Escolar Documentos
Profissional Documentos
Cultura Documentos
OSTEOBLASTS AND
BONE F O R M AT I O N
Abstract Resumo
Bone is constantly being remodelled in a dynamic O osso est em constante remodelao num pro-
process where osteoblasts are responsible for bone cesso dinmico, em que os osteoblastos so res-
formation and osteoclasts for its resorption. ponsveis pela sua formao e os osteoclastos pela
Osteoblasts are specialized mesenchymal cells sua reabsoro.
that undergo a process of maturation where genes Os osteoblastos derivam de clulas mesen-
like core-binding factor 1 (Cbfa1) and osterix (Osx) quimatosas que sofreram um processo de ma-
play a very important role. Moreover, it was found turao, no qual genes como o core-binding factor
recently that the Wnt/-catenin pathway plays a 1 (Cbfa1) e osterix (Osx) assumem um papel de
part on osteoblast differentiation and proliferation. grande importncia. Foi descoberto recentemente
In fact, mutations on some of the proteins involved que a via de sinalizao Wnt/-catenina tem um
in this pathway, like the low-density lipoprotein re- papel relevante na diferenciao e proliferao do
ceptor related protein 5/6 (LRP5/6), lead to bone di- osteoblasto. Na realidade, mutaes em deter-
seases. minadas protenas envolvidas nesta via, como
Osteoblasts have also a role in the regulation of o co-receptor low-density lipoprotein receptor re-
bone resorption through receptor activator of nu- lated protein 5/6 (LRP5/6), so causa de doenas
clear factor-B (RANK) ligand (RANKL), that links sseas.
to its receptor, RANK, on the surface of pre-osteo- Os osteoblastos desempenham tambm um pa-
clast cells, inducing their differentiation and fu- pel importante na regulao da reabsoro ssea
sion. On the other hand, osteoblasts secrete a so- atravs do receptor activator of nuclear factor-B
luble decoy receptor (osteoprotegerin, OPG) that (RANK) ligand (RANKL) que interage com o seu re-
blocks RANK/RANKL interaction by binding to ceptor RANK, expresso na superfcie de pr-osteo-
RANKL and, thus, prevents osteoclast differentia- clastos, induzindo a diferenciao e fuso destas
tion and activation. Therefore, the balance betwe- clulas. Por outro lado, os osteoblastos secretam
en RANKL and OPG determines the formation and um receptor solvel, a osteoprotegerina (OPG), que
activity of osteoclasts. bloqueia a interaco RANK/RANKL atravs da sua
Another factor that influences bone mass is lep- ligao ao RANKL, prevenindo assim a diferencia-
tin, a hormone produced by adipocytes that have o e activao do osteoclasto. Desta forma, o ba-
a dual effect. It can act through the central nervous lano entre RANKL e OPG determina a formao e
system and diminish osteoblasts activity, or can actividade do osteoclasto.
have an osteogenic effect by binding directly to its Outro factor que influencia a massa s-
receptors on the surface of osteoblast cells. sea a leptina, uma hormona produzida pelos
adipcitos, que tem um efeito duplo. Pode actuar
Keywords: Osteoblasts; Bone Formation; Wnt/- atravs do sistema nervoso central e diminuir a
-catenin Signalling; Leptin; Cbfa1. actividade do osteoblasto, ou pode exercer um
efeito osteognico atravs da interaco com os
receptores presentes na superfcie do osteo-
blasto.
*Unidade de Investigao em Reumatologia, Instituto de Medicina
Molecular, Faculdade de Medicina da Universidade de Lisboa
**Servio de Reumatologia e Doenas sseas Metablicas, Palavras-chave: Osteoblastos; Formao do Osso;
Hospital de Santa Maria Sinalizao Wnt/-catenina; Leptina; Cbfa1.
R G O O F I C I A L D A S O C I E D A D E P O R T U G U E S A D E R E U M AT O L O G I A - A C TA R E U M P O R T . 2 0 0 7 ; 3 2 : 1 0 3 - 1 1 0
103
O S T E O B L A S T S A N D B O N E F O R M AT I O N
Osteoblasts
R G O O F I C I A L D A S O C I E D A D E P O R T U G U E S A D E R E U M AT O L O G I A - A C TA R E U M P O R T . 2 0 0 7 ; 3 2 : 1 0 3 - 1 1 0
104
J O A N A C A E TA N O - L O P E S E C O L .
R G O O F I C I A L D A S O C I E D A D E P O R T U G U E S A D E R E U M AT O L O G I A - A C TA R E U M P O R T . 2 0 0 7 ; 3 2 : 1 0 3 - 1 1 0
105
O S T E O B L A S T S A N D B O N E F O R M AT I O N
the expression of an early osteoblast marker, alka- the default pathway for the cells that do not recei-
line phosphatase (ALP). Although this signalling ve proper inductive signals to become osteoblasts,
pathway is involved in the regulation of osteoblas- chondrocytes, myocytes or other mesodermal
togenesis and bone formation, a specific Wnt pro- cells.12 As a matter of fact, a relationship between
tein that triggers its activation has still not been osteoblast and adipocyte differentiation might ex-
identified.15 In fact, several Wnt genes, such as ist, where an increase in osteoblast differentiation
Wnt1, Wnt4, Wnt5, Wnt9/14 and Wnt7b are ex- is associated with a decrease in adipocyte differen-
pressed in either osteoblast precursors or adjacent tiation.
tissues during development, and Wnt3 and Wnt signalling is tightly regulated by secreted
Wnt10b are expressed in bone marrow,13 but only antagonists. An example of this regulation is the in-
Wnt10b mutants express a postnatal decrease in teraction of Wnt with the receptor Fz which is in-
bone mass.3 The expression of Wnt10b in mesen- hibited by members of the secreted frizzled-rela-
chymal progenitor cells, in vitro, induces the ex- ted protein family (sFRP) and Wnt inhibitory fac-
pression of the transcription factors core binding tor (WIF-1).12 On the other hand, LRP5/6 activity is
factor 1 (Cbfa1), Distal-less homeobox 5 (Dlx5) antagonized by sclerostin (encoded by the SOST
and Osx, stimulating osteoblastogenesis. These gene) and members of the Dkk family.13 Canonical
observations substantiate the fact that Wnt signal- Wnts upregulate Dkk2 expression which, in turn,
ling influences the differentiation of the precursor controls some of the processes required for termi-
cells by increasing the expression of key osteoblas- nal osteoblast differentiation, mostly by removing
togenic transcription factors15 (Figure 3). On the the cells from the cell cycle. In fact, Dkk2 is impor-
other hand, Wnt10b inhibits the transcription fac- tant in late stages of osteogenic differentiation,
tors CCAAT/enhancer-binding protein (C/EBP) particularly for the formation of mineralized ma-
and peroxisome proliferator-activated receptor trix.16 LRP5 and LRP6 are receptors for the Wnts
(PPAR), blocking adipogenesis.15 Thus, Wnts have and for other types of molecules such as scleros-
also a role on mesenchymal precursor cells linea- tin, which is produced by osteocytes, inhibiting the
ge commitment and adipogenesis is most likely proliferation and maturation of osteoblasts and
promoting their apoptosis. Mutations that reduce
SOST function, in humans, cause abnormal growth
of bone tissue, giving rise to a disease named scle-
rosteosis. Also, the function of mature osteoblasts,
including the ability to synthesize extracelular ma-
trix proteins requires LRP5 as well as the signalling
protein activating-transcription factor 4 (ATF4).5
Wnt/-catenin pathway acts by attenuating os-
teoclastogenesis13 through transcriptional regula-
tion of OPG, since the expression of this molecule
was found to be upregulated by canonical Wnt sig-
nalling in an in vitro screen for Wnt-regulated ge-
nes. OPG is also a direct target of the -catenin-Tcf
complex in osteoblasts, and Tcf1 is probably a
Figure 3. Mesenchymal precursor cells give rise to transcription factor required for OPG regulation.3
several cell types, among which are osteoblasts.
ALP alkaline phosphatase; ATF4 activating Genes expressed in osteoblasts
transcription factor 4; cbfa1 core binding factor 1; Osteoblasts derive from mesenchymal precursor
COL1 collagen type I1; C/EBP - CCAAT/ cells8,17 which also originate chondrocytes, myo-
/enhancer-binding protein ; Dlx5 distal-less homeobox blasts, adipocytes and tendon cells, depending on
5; LRP5/6 low density lipoprotein receptor related the transcription factors that regulate the path-
protein 5/6; Osx osterix; OPN osteopontin;
way.4,5,18 Three of these transcription factors are
PPAR peroxisome proliferators-activated receptor ;
RANKL receptor activator of nuclear factor-B ligand.
Cbfa1, Osx and ATF4, which have been identified
(Osteoblasts and osteoclasts symbols were adapted from as controllers of the osteoblastic lineage.5,18 In the
Rheugulation Database, knowledge base on rheumatoid absence of Cbfa1 and Osx, no osteoblasts are for-
arthritis, www.rheugulationdb.com) med. Also, bone morphogenic proteins (BMPs),
R G O O F I C I A L D A S O C I E D A D E P O R T U G U E S A D E R E U M AT O L O G I A - A C TA R E U M P O R T . 2 0 0 7 ; 3 2 : 1 0 3 - 1 1 0
106
J O A N A C A E TA N O - L O P E S E C O L .
R G O O F I C I A L D A S O C I E D A D E P O R T U G U E S A D E R E U M AT O L O G I A - A C TA R E U M P O R T . 2 0 0 7 ; 3 2 : 1 0 3 - 1 1 0
107
O S T E O B L A S T S A N D B O N E F O R M AT I O N
R G O O F I C I A L D A S O C I E D A D E P O R T U G U E S A D E R E U M AT O L O G I A - A C TA R E U M P O R T . 2 0 0 7 ; 3 2 : 1 0 3 - 1 1 0
108
J O A N A C A E TA N O - L O P E S E C O L .
by the white adipose tissue.23 It acts by binding to cells, leptin expression is present and in prolifera-
a hypothalamus receptor and regulates body ting osteoblasts is suppressed, while it reappears
weight through appetite suppression and increa- in late stage osteoblasts. Accordingly, it can be ar-
sed energy expending.4 Leptin is known to act in gued that leptin increases bone formation by
the immune system, reproduction, development, enhancing human osteoblast proliferation, colla-
hematopoiesis, angiogenesis and in the skeletal gen synthesis and mineralization.43 Moreover, lep-
tissue.38 tin serves as an osteoblastic antiapoptotic agent by
Two opposing mechanisms have been sugges- reducing the mRNA levels of Bax-/Bcl-2, which
ted to explain the effect of leptin on bone metabo- facilitate the transition of mature osteoblasts to os-
lism. On one hand, leptin can act locally to promo- teocytes.39,43
te the development of osteoprogenitor cells and Due to the fact that RANKL and OPG are invol-
stimulate osteoblasts to form new bone and, on ved in the interaction between osteoblasts and os-
the other hand, leptin can act through the central teoclasts, the influence of leptin upon these mole-
nervous system decreasing osteoblast activity23 (Fi- cules was investigated. In an in vitro study, it was
gure 4). Mice genetically deficient in leptin, or lep- found that leptin decreases RANKL mRNA expres-
tin receptor, have an obese phenotype, with a high sion but had no effect on OPG mRNA levels.23 This
bone mass.2,38 However, when leptin is injected in- observation raised the hypothesis that leptin can
tracerebroventricularly, there is a decrease in bone- affect bone remodelling through the RANKL/OPG
forming activity and a return to the bone mass seen pathway. This effect may depend on leptin serum
in a wild-type mice, suggesting that leptin acts levels which, in humans, are influenced by food
through a central pathway after binding to its re- intake, periods of growth and reproduction.23.
ceptor in the hypothalamic nuclei.38,39 In addition,
increased serum levels of leptin decrease bone
mass suggesting that serum levels of this hormo- Conclusions
ne might control bone mass through a neuronal
pathway.40 It is still unclear which are the mecha- Cbfa1 and Osx genes are critical in osteoblast dif-
nisms relating leptin, central nervous system and ferentiation. In addition, the Wnt/-catenin path-
bone. However, it is known that in the hypothala- way plays a role not only on osteoblast differenti-
mic nuclei leptin receptors are co expressed in neu- ation but also on its proliferation. In fact, muta-
rons expressing the appetite-suppressing neuro- tions in some of the proteins involved in this path-
peptides proopiomelanocortin (POMC) and cocai- way, like LRP5/6 lead to bone diseases. Osteoblasts
ne-and amphetamine-regulated transcript (CART) are also influenced by leptin in a dual way: inhibi-
and in neurons expressing the appetite-inducing tory, through the central nervous system, or sti-
neuropeptide Y (NPY) and agouti-related peptide mulatory through the direct binding on surface re-
(AgRP). Interestingly, intracerebroventricular in- ceptors. On the other hand, osteoblasts are res-
jection of leptin results in reduced expression of ponsible for the RANKL/OPG balance which is the
NPY and AgRP and increased expression of POMC. major determinant of osteoclast differentiation.
Thus, this provides preliminary evidence that the Although most of the current therapeutic opti-
melanocortin pathway might be involved in leptin ons for osteoporosis antagonize bone resorption,
signalling, at least for its appetite regulator role.41 the increasing knowledge on osteoblast regulation
When leptin acts directly on osteoblast and is creating new hypothetical targets that can trans-
chondrocyte surface receptors it can have an os- form the future of osteoporosis management.
teogenic effect.38,39 There are six isoforms of the lep-
tin receptor (OB-R), created by different splicing Correspondence to:
variants of the gene ob, but only four of them (OB- Joo Eurico Fonseca
-Ra, OB-Rb, OB-Rc and OB-Rf) are expressed on Unidade de Investigao em Reumatologia, Instituto
de Medicina Molecular, Faculdade de Medicina da
osteoblasts. From these, just OB-Ra and OB-Rb are
Universidade de Lisboa, Edifcio Egas Moniz
able to mediate leptin-induced signalling trans- Av. Professor Egas Moniz, 1649-028 Lisboa, Portugal
duction into the cell.42 It was also found that pri- E-mail: jefonseca@netcabo.pt
mary human osteoblasts transcribe, translate and
secrete leptin and that leptin expression fluctuates References
during its differentiation. In fact, in mesenchymal 1. Seeman E, Delmas PD. Bone qualitythe material and
R G O O F I C I A L D A S O C I E D A D E P O R T U G U E S A D E R E U M AT O L O G I A - A C TA R E U M P O R T . 2 0 0 7 ; 3 2 : 1 0 3 - 1 1 0
109
O S T E O B L A S T S A N D B O N E F O R M AT I O N
structural basis of bone strength and fragility. N Engl J Med 24. Kim HH, Shin HS, Kwak HJ, et al. RANKL regulates endothelial
2006; 354: 2250-2261. cell survival through the phosphatidylinositol 3-kinase/Akt
2. Ducy P, Schinke T, Karsenty G. The osteoblast: a sophistica- signal transduction pathway. Faseb J 2003;17:2163-2165.
ted fibroblast under central surveillance. Science 2000; 289: 25. Kartsogiannis V, Zhou H, Horwood NJ, et al. Localization of
1501-1504. RANKL (receptor activator of NF kappa B ligand) mRNA and
3. Hartmann C. A Wnt canon orchestrating osteoblastogenesis. protein in skeletal and extraskeletal tissues. Bone 1999; 25:
Trends Cell Biol 2006; 16: 151-158. 525-534.
4. Harada S, Rodan GA. Control of osteoblast function and re- 26. Hofbauer LC, Heufelder AE. Role of receptor activator of nu-
gulation of bone mass. Nature 2003; 423: 349-355. clear factor-kappaB ligand and osteoprotegerin in bone cell
5. Krane SM. Identifying genes that regulate bone remodeling biology. J Mol Med 2001; 79: 243-253.
as potential therapeutic targets. J Exp Med 2005; 201: 841- 27. Ali AS, Lax AS, Liljestrom M, et al. Mast cells in atherosclero-
-843. sis as a source of the cytokine RANKL. Clin Chem Lab Med
6. Gori F, Hofbauer LC, Dunstan CR, Spelsberg TC, Khosla S, 2006; 44: 672-674.
Riggs BL. The expression of osteoprotegerin and RANK li- 28. Theoleyre S, Wittrant Y, Tat SK, Fortun Y, Redini F, Heymann
gand and the support of osteoclast formation by stromal-os- D. The molecular triad OPG/RANK/RANKL: involvement in
teoblast lineage cells is developmentally regulated. Endocri- the orchestration of pathophysiological bone remodeling.
nology 2000; 141: 4768-4776. Cytokine Growth Factor Rev 2004; 15: 457-475.
7. Canho H, Fonseca JE, Queiroz MV. Epidemiologia da osteo- 29. Khosla S. Minireview: the OPG/RANKL/RANK system. En-
porose. Mecanismos de remodelao ssea e factores pro- docrinology 2001; 142: 5050-5055.
tectores do osso. Acta Reumatolgica Portuguesa 2005; 30: 30. Atkins GJ, Kostakis P, Pan B, et al. RANKL expression is rela-
225-240. ted to the differentiation state of human osteoblasts. J Bone
8. Mackie EJ. Osteoblasts: novel roles in orchestration of skele- Miner Res 2003; 18: 1088-1098.
tal architecture. Int J Biochem Cell Biol 2003; 35: 1301-1305. 31. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin:
9. Knothe Tate ML, Adamson JR, Tami AE, Bauer TW. The oste- a novel secreted protein involved in the regulation of bone
ocyte. Int J Biochem Cell Biol 2004; 36: 1-8. density. Cell 1997; 89: 309-319.
10. Manolagas SC. Birth and death of bone cells: basic regula- 32. Yasuda H, Shima N, Nakagawa N, et al. Identity of osteoclas-
tory mechanisms and implications for the pathogenesis and togenesis inhibitory factor (OCIF) and osteoprotegerin
treatment of osteoporosis. Endocr Rev 2000; 21: 115-137. (OPG): a mechanism by which OPG/OCIF inhibits osteo-
11. Cadigan KM, Liu YI. Wnt signaling: complexity at the surfa- clastogenesis in vitro. Endocrinology 1998; 139: 1329-1337.
ce. J Cell Sci 2006; 119: 395-402. 33. Yamaguchi K, Kinosaki M, Goto M, et al. Characterization of
12. Westendorf JJ, Kahler RA, Schroeder TM. Wnt signaling in structural domains of human osteoclastogenesis inhibitory
osteoblasts and bone diseases. Gene 2004; 341: 19-39. factor. J Biol Chem 1998; 273: 5117-5123.
13. Krishnan V, Bryant HU, Macdougald OA. Regulation of bone 34. Yamada Y, Ando F, Niino N, Shimokata H. Association of
mass by Wnt signaling. J Clin Invest 2006; 116: 1202-1209. polymorphisms of the osteoprotegerin gene with bone mi-
14. He X, Semenov M, Tamai K, Zeng X. LDL receptor-related neral density in Japanese women but not men. Mol Genet
proteins 5 and 6 in Wnt/beta-catenin signaling: arrows point Metab 2003; 80: 344-349.
the way. Development 2004; 131: 1663-1677. 35. Arko B, Prezelj J, Komel R, Kocijancic A, Hudler P, Marc J. Se-
15. Bennett CN, Longo KA, Wright WS, et al. Regulation of oste- quence variations in the osteoprotegerin gene promoter in
oblastogenesis and bone mass by Wnt10b. Proc Natl Acad patients with postmenopausal osteoporosis. J Clin Endocri-
Sci U S A 2005; 102: 3324-3329. nol Metab 2002; 87: 4080-4084.
16. Li X, Liu P, Liu W, et al. Dkk2 has a role in terminal osteoblast 36. Walsh MC, Choi Y. Biology of the TRANCE axis. Cytokine
differentiation and mineralized matrix formation. Nat Genet Growth Factor Rev 2003; 14: 251-263.
2005; 37: 945-952. 37. Wada T, Nakashima T, Hiroshi N, Penninger JM. RANKL-
17. Karsenty G. The complexities of skeletal biology. Nature RANK signaling in osteoclastogenesis and bone disease.
2003; 423: 316-318. Trends Mol Med 2006; 12: 17-25.
18. Stains JP, Civitelli R. Genomic approaches to identifying 38. Cock TA, Auwerx J. Leptin: cutting the fat off the bone. Lan-
transcriptional regulators of osteoblast differentiation. Ge- cet 2003; 362: 1572-1574.
nome Biol 2003; 4: 222. 39. Reseland JE, Gordeladze JO. Role of leptin in bone growth:
19. Thomas GP, Baker SU, Eisman JA, Gardiner EM. Changing central player or peripheral supporter? FEBS Lett 2002; 528:
RANKL/OPG mRNA expression in differentiating murine 40-42.
primary osteoblasts. J Endocrinol 2001; 170: 451-460. 40. Elefteriou F, Takeda S, Ebihara K, et al. Serum leptin level is a
20. Kodaira K, Kodaira K, Mizuno A, et al. Cloning and characte- regulator of bone mass. Proc Natl Acad Sci U S A 2004; 101:
rization of the gene encoding mouse osteoclast differentiati- 3258-3263.
on factor. Gene 1999; 230: 121-127. 41. Plum L, Ma X, Hampel B, et al. Enhanced PIP3 signaling in
21. Anderson DM, Maraskovsky E, Billingsley WL, et al. A homo- POMC neurons causes KATP channel activation and leads to
logue of the TNF receptor and its ligand enhance T-cell diet-sensitive obesity. J Clin Invest 2006; 116: 1886-1901.
growth and dendritic-cell function. Nature 1997; 390: 175-179. 42. Lee YJ, Park JH, Ju SK, You KH, Ko JS, Kim HM. Leptin recep-
22. Lam J, Nelson CA, Ross FP, Teitelbaum SL, Fremont DH. tor isoform expression in rat osteoblasts and their functional
Crystal structure of the TRANCE/RANKL cytokine reveals analysis. FEBS Lett 2002; 528: 43-47.
determinants of receptor-ligand specificity. J Clin Invest 43. Gordeladze JO, Drevon CA, Syversen U, Reseland JE. Leptin
2001; 108: 971-979. stimulates human osteoblastic cell proliferation, de novo
23. Lamghari M, Tavares L, Camboa N, Barbosa MA. Leptin ef- collagen synthesis, and mineralization: Impact on differen-
fect on RANKL and OPG expression in MC3T3-E1 osteob- tiation markers, apoptosis, and osteoclastic signaling. J Cell
lasts. J Cell Biochem 2006; 98: 1123-1129. Biochem 2002; 85: 825-836.
R G O O F I C I A L D A S O C I E D A D E P O R T U G U E S A D E R E U M AT O L O G I A - A C TA R E U M P O R T . 2 0 0 7 ; 3 2 : 1 0 3 - 1 1 0
110